Diabetic foot infection is a frequent and potentially life-threatening complication of diabetes mellitus. Antibiotic treatment is the cornerstone of management of diabetic foot infection but the rising prevalence of antibiotic resistance has resulted in increasing rates of treatment failure. In this context, the development of several novel antibiotics might represent a useful tool in severe diabetic foot infections caused by multidrug-resistant bacteria. In the present review, we summarize the safety and efficacy of novel antibiotics in patients with diabetic foot infection. Relevant data are limited, and randomized controlled studies that evaluated the role of these agents in this field are lacking. Until more robust data are available, cefiderocol and dalbavancin, which have been studied more extensively in patients with bone infections, might be attractive options in carefully selected patients with severe diabetic foot infection.
Keywords: Antibiotics; Cefiderocol; Ceftaroline; Ceftazidime/avibactam; Ceftolozane/azobactam; Dalbavancin; Diabetes mellitus; Diabetic foot infection; Imipenem-cilastatin/relebactam; Meropenem/vaborbactam; Oritavancin; Plazomicin; Tedizolid.
© 2022. The Author(s).